New drug for prostate cancer

Plenaxis® (abarelix) is our lead product. It is the first in a new class of hormonal products to treat advanced and metastatic prostate cancer.

Plenaxis® is a gonadotrophin-releasing hormone receptor (GnRH) blocker and it works by direct blockade of the GnRH receptors, resulting in a rapid and sustained reduction in testosterone levels and rapid and sustained disease control. As a result, Plenaxis® is the first antagonist hormonal for managing prostate cancer that overcomes the need for anti-androgen co-prescribing. It has a rapid onset and offset of action, leading to fast and profound PSA and prostate volume reduction.

Clinical studies have shown that no hormonal surge or clinical flare occurs with Plenaxis® (unlike with agonist hormonal therapy), the efficacy is equal to the combined use of an agonist and anti-androgen and the effects on testosterone are reversible on stopping treatment.

Plenaxis® is available in Germany and is undergoing registration across Europe.

Further information is available on request.

Regurin® XL (prolonged release trospium chloride) is a new, once daily version of Regurin®. It is one of a group of medicines called ‘anticholinergics’.

Regurin XL is indicated to help control the symptoms of overactive bladder that cause a frequent need to go to the toilet (urinary frequency), needing to suddenly rush to the toilet (urgency) and/or not getting there in time (urge incontinence).

Trospium chloride is one of the anticholinergics approved by NICE for the treatment of urinary incontinence in women.

Further information on Regurin XL

Click here if you are a healthcare professional

Click here if you are a pharmacist

Click here if you are a patient or other non-healthcare professional

Regurin (trospium chloride) is available in packs of 60 tablets and is used twice daily to treat the symptoms of overactive bladder

Further information on Regurin

Click here if you are a healthcare professional

Click here if you are not a healthcare professional

Both Regurin XL and Regurin are available in the UK as prescription-only medicines.

Regurin is also available on prescription in Ireland.

Haemopressin® (terlipressin) is a critical care product for the treatment of bleeding oesophageal varices.

Speciality European Pharma recently sold the worldwide right to Haemopressin® to Maelor plc, enabling us to focus our corporate resources on developing our urology franchise. As part of the agreement, Speciality European Pharma retains the Haemopressin® distribution rights for France and Italy.